Skip to main content
TipRanks
Go Ultimate75% OFF

Viemed Healthcare (VIJ) AI Stock Analysis

1 Followers
DE:VIJ

Viemed Healthcare

(Frankfurt:VIJ)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Sustained Revenue GrowthViemed has delivered sustained top-line expansion across several years, reaching $310.4 million in TTM revenue. This indicates growing adoption of its home-based care model and provides a durable base for further scale, investment, and earnings growth.
Negative Factors
Margin CompressionAlthough revenue is growing quickly, lower operating and EBITDA margins show that earnings are not expanding as efficiently as sales. If this pattern persists, Viemed may need continued volume growth to offset weaker profitability and preserve earnings momentum.

Viemed Healthcare (VIJ) vs. iShares MSCI Germany ETF (EWG)

-20%0%20%40%60%80%100%120%DE:VIJ+52.88%EWG+9.30%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 343.69M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
22.3
Beta (1Y)
0.28
Revenue Growth
16.05%
EPS Growth
11.93%
Country
Germany
Employees
1,490
Sector
Healthcare
Sector Strength
51
Industry
Medical - Care Facilities

Viemed Healthcare Business Overview & Revenue Model

Company Description

Viemed Healthcare, Inc., through its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The company provides respiratory disease management solutions, including treatment of chroni...

Viemed Healthcare Earnings Call Summary

Earnings Call Date:Nov 04, 2026(Q3-2026)|% Change Since:-10.67%|Next Earnings Date:Mar 10, 2027
Earnings Call SentimentPositive

The call was broadly positive, led by record revenue, double-digit organic growth, strong net income and adjusted EBITDA expansion, growing sleep and maternal health volumes, improving ventilation revenue, capital returns, and higher revenue guidance. The primary challenges were slightly lower gross margin, increased audit-related work and payment timing, temporarily weaker cash conversion, volatility in ventilation active patients, and a lower upper end to adjusted EBITDA guidance.

Positive Updates

Record Revenue and Strong Net Income Growth
Third-quarter revenue reached a record $80.7 million, up 12.2% year over year. Net income attributable to Viemed increased 32% year over year to $4.6 million, or $0.11 per diluted share, and rose approximately 68% from the second quarter.

Negative Updates

Gross Margin Declined Slightly
Gross profit was $46.2 million, or 57.3% of revenue, compared with 57.5% a year ago and 57.7% in the second quarter. Management attributed the year-over-year margin effect to the shift toward equipment and supply sales, which generally carry lower margins than equipment rentals.

Company Guidance

Management now expects full-year revenue of $316 million to $320 million, compared with the previous range of $314 million to $320 million; adjusted EBITDA guidance is $64 million to $66 million, compared with the previous range of $64 million to $68 million; and net CapEx is expected to be 8% to 9% of revenue, compared with 8.5% to 10% previously. The revised outlook anticipates sequential growth in both revenue and adjusted EBITDA in the fourth quarter and excludes any potential future acquisitions or strategic transactions. Viemed is on track to enter 2 additional states per quarter beginning in the fourth quarter for maternal health, expects ventilator active patient count to be back up in the fourth quarter, and expects to stay up in the 20-plus percent adjusted EBITDA for the time being.

Viemed Healthcare Risk Analysis

Viemed Healthcare disclosed 39 risk factors in its most recent earnings report. Viemed Healthcare reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Viemed Healthcare Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:VIJ against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ADUSADUS83Outperform$2.27B20.389.81%―11.53%27.72%
EHCEHC70Outperform$13.53B21.4625.17%0.57%9.36%20.78%
NHCNHC68Neutral$3.22B27.8510.41%1.27%5.71%12.44%
AVAHAVAH65Neutral$2.54B7.94115.53%―16.84%280.13%
PNTGPNTG61Neutral$1.28B35.3610.15%―38.67%33.07%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

0%50%100%DE:VIJADUSEHCNHCPNTGAVAHDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:VIJ and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:VIJViemed Healthcare US7.952.8054.37%
ADUSAddus HomeCare Corporation121.5611.4910.44%
EHCEncompass Health137.8825.9223.15%
NHCNational Healthcare205.7780.2963.98%
PNTGPennant Group Inc36.5010.5940.87%
AVAHAveanna Healthcare Holdings Inc11.653.3540.36%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.